|
Ayala Pharmaceuticals Inc (ADXS) |
|
Ayala Pharmaceuticals Inc
ADXS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Ayala Pharmaceuticals Inc 's sales fell
in IV. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Ayala Pharmaceuticals Inc net loss increased from $-5 millions, to $-25 millions in IV. Quarter 2023,
• More on ADXS's Growth
|
|
Ayala Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.07 in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 12.5.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.96.
• More on ADXS's Valuation
|
|
|
|
|
Ayala Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.07 in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 12.5.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.96.
• More on ADXS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com